| 0 (0%) | 12-05 09:29 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.81 | 1-year : | 17.29 |
| Resists | First : | 12.68 | Second : | 14.81 |
| Pivot price | 11.95  |
|||
| Supports | First : | 11.01 | Second : | 9.98 |
| MAs | MA(5) : | 12.19 |
MA(20) : | 11.88 |
| MA(100) : | 9.98 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 50.3 |
D(3) : | 59.8 |
| RSI | RSI(14): 56.3 |
|||
| 52-week | High : | 12.68 | Low : | 6.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMRX ] has closed above bottom band by 48.9%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.25 - 12.32 | 12.32 - 12.38 |
| Low: | 11.51 - 11.6 | 11.6 - 11.68 |
| Close: | 11.8 - 11.94 | 11.94 - 12.06 |
Fri, 05 Dec 2025
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Thu, 04 Dec 2025
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects - simplywall.st
Wed, 03 Dec 2025
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
Wed, 03 Dec 2025
Is It Too Late To Consider Amneal Pharmaceuticals After Its 425.4% Three Year Surge? - simplywall.st
Tue, 02 Dec 2025
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - Sahm
Tue, 02 Dec 2025
Amneal (Nasdaq: AMRX) adds 2nd Q4 2025 inhaler with FDA approval in $1.5B market - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 314 (M) |
| Shares Float | 191 (M) |
| Held by Insiders | 46.4 (%) |
| Held by Institutions | 49.2 (%) |
| Shares Short | 6,580 (K) |
| Shares Short P.Month | 5,750 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0.2 % |
| Operating Margin | 11.8 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 11.6 % |
| Gross Profit (p.s.) | 3.46 |
| Sales Per Share | 9.32 |
| EBITDA (p.s.) | 1.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 328 (M) |
| Levered Free Cash Flow | 219 (M) |
| PE Ratio | 1194 |
| PEG Ratio | 0 |
| Price to Book value | -34.12 |
| Price to Sales | 1.28 |
| Price to Cash Flow | 11.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|